Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors - PubMed (original) (raw)
- PMID: 3159472
- PMCID: PMC11039082
- DOI: 10.1007/BF00199229
Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors
I Bursuker et al. Cancer Immunol Immunother. 1985.
Abstract
Infusion of normal recipient mice with suppressor T cells from donors bearing a progressive Meth A fibrosarcoma results in a diminished capacity of the recipients to generate concomitant and postexcision antitumor immunity. The passive transfer of suppressor cells which prevented the generation of immunity to the Meth A fibrosarcoma did not affect the capacity of the recipients to reject an allogeneic tumor. The data provides direct evidence in support of the hypothesis that suppressor T cells, generated at later stages of growth of Meth A fibrosarcoma, function to down-regulate an already acquired mechanism of concomitant immunity.
Similar articles
- Induction of antitumor immunity by tumor cells treated with abrin.
Shionoya H, Arai H, Koyanagi N, Ohtake S, Kobayashi H, Kodama T, Kato H, Tung TC, Lin JY. Shionoya H, et al. Cancer Res. 1982 Jul;42(7):2872-6. Cancer Res. 1982. PMID: 7083176 - Tumor immunology with particular reference to malignant melanoma.
Maguire HC Jr. Maguire HC Jr. Int J Dermatol. 1975 Jan-Feb;14(1):3-11. doi: 10.1111/j.1365-4362.1975.tb00071.x. Int J Dermatol. 1975. PMID: 1092622 Review. No abstract available. - Differential antigen presentation in tumor immunity.
Schatten S, Drebin JA, Granstein RD, Greene MI. Schatten S, et al. Fed Proc. 1984 Jun;43(9):2460-4. Fed Proc. 1984. PMID: 6327399 Review.
Cited by
- Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Duhen T, Gough MJ, Leidner RS, Stanton SE. Duhen T, et al. Front Oral Health. 2022 Jul 22;3:902160. doi: 10.3389/froh.2022.902160. eCollection 2022. Front Oral Health. 2022. PMID: 35937775 Free PMC article. Review. - Defining Immunogenic and Radioimmunogenic Tumors.
Medler TR, Blair TC, Crittenden MR, Gough MJ. Medler TR, et al. Front Oncol. 2021 Mar 19;11:667075. doi: 10.3389/fonc.2021.667075. eCollection 2021. Front Oncol. 2021. PMID: 33816320 Free PMC article. Review. - Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Zhou G, et al. J Exp Med. 2004 Dec 20;200(12):1581-92. doi: 10.1084/jem.20041240. Epub 2004 Dec 13. J Exp Med. 2004. PMID: 15596524 Free PMC article. - Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Turk MJ, et al. J Exp Med. 2004 Sep 20;200(6):771-82. doi: 10.1084/jem.20041130. J Exp Med. 2004. PMID: 15381730 Free PMC article. - Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation.
Ebina T, Kohya H. Ebina T, et al. Jpn J Cancer Res. 1988 Aug;79(8):957-64. doi: 10.1111/j.1349-7006.1988.tb00061.x. Jpn J Cancer Res. 1988. PMID: 3141330 Free PMC article.
References
- Bonventre PF, Nikol AD, Ball EJ, Michael JG, Bubel HC. Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity. J Reticuloendothel Soc. 1982;32:25. - PubMed
- Dye ES, North RJ. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukocyte Biol. 1984;36:27. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources